Bayer Migraine Formula Seeks Market Share Before Excedrin Returns
This article was originally published in The Tan Sheet
Executive Summary
Bayer Migraine Formula, already in major retailers nationwide, is “a welcome addition to the pain relief aisle for migraine sufferers … affected by the OTC supply issues this year,” the firm says, referring to Novartis’ voluntarily recall of Excedrin.
You may also be interested in...
GelStat Breaks Into Retail With Migraine Remedy
CEO Larry Gershman says GelStat will launch a marketing campaign to support extending its products for the first time to retail stores. The firm changed its sublingual migraine homeopathic to a single dose from two doses taken five minutes apart.
GelStat Breaks Into Retail With Migraine Remedy
CEO Larry Gershman says GelStat will launch a marketing campaign to support extending its products for the first time to retail stores. The firm changed its sublingual migraine homeopathic to a single dose from two doses taken five minutes apart.
Bayer Aims For Global OTC Lead With Bolt-On Acquisition Plans
Chairman Marijn Dekkers says the German company believes strong organic growth and consumer health pick-ups will help Bayer become the world leader in OTCs.